AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC.
The fund invests in public equity markets across the globe.
It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
The fund primarily invests in growth stocks of small cap companies.
It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio.
The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index.
It was formerly known as H&Q Life Sciences Investors fund.
Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Country | United States |
IPO Date | May 1, 1992 |
Industry | Asset Management |
Sector | Financial Services |
Employees | n/a |
CEO | Dr. Daniel R. Omstead M.S, Ph.D. |
Contact Details
Address: 100 Federal Street Boston, Massachusetts United States | |
Website | https://www.teklacap.com/hql.html |
Stock Details
Ticker Symbol | HQL |
Exchange | NYSE |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0000884121 |
CUSIP Number | 87911K100 |
ISIN Number | US87911K1007 |
Employer ID | 04-3147016 |
SIC Code |
Key Executives
Name | Position |
---|---|
Dr. Daniel R. Omstead M.S, Ph.D. | Principal Executive Officer, President and Trustee |
Peter Branner | Chief Investment Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 20, 2024 | 3 | Filing |
Dec 20, 2024 | 3 | Filing |
Dec 16, 2024 | N-CEN | Filing |
Dec 09, 2024 | N-CSR | Filing |
Nov 27, 2024 | NPORT-P | Filing |
Sep 03, 2024 | N-PX | Filing |
Aug 28, 2024 | NPORT-P | Filing |
Aug 27, 2024 | 4 | Filing |
Aug 15, 2024 | 40-17G | Filing |
Jul 18, 2024 | 4 | Filing |